Objective: Lobectomy is considered optimal therapy for early-stage non-small cell lung cancer, but sublobar wedge resection and stereotactic body radiation therapy are alternative treatments. This study compared outcomes between wedge resection and stereotactic body radiotherapy.
Perspective
We compared stereotactic body radiotherapy and wedge resection for patients with clinicalstage IA non-small cell lung cancer using a national database and found a survival advantage associated with wedge resection. These results highlight the need for multidisciplinary involvement in the evaluation of patients with early-stage non-small cell lung cancer.
See Editorial Commentary page 687.
As implementation of lung cancer screening increases, the percentage of patients with early-stage lung cancer is likely to rise, increasing the opportunity for surgical management. Margin-negative anatomic surgical resection with systematic lymph node evaluation is considered the standard of care for early-stage non-small cell lung cancer (NSCLC) in patients who can tolerate surgery. 1 An operative alternative to anatomic resection includes surgical wedge resection. 2, 3 There are a subset of patients with small, peripheral lesions who are considered high risk for surgery based on their underlying lung function and/or medical comorbidities. Because the impact of wedge resection on lung function is minimal and the physiologic impact of surgery well-tolerated by most patients, these patients were managed, historically, with wedge resection for local control as the only alternative to definitive nonoperative treatments. Over the past decade, however, stereotactic body radiation therapy (SBRT) has been proposed as a viable alternative. 4, 5 Initially, SBRT was used primarily to treat patients with NSCLC deemed inoperable secondary to other medical conditions or poor pulmonary function. SBRT now is also being actively investigated to determine its role in the management of patients who can tolerate surgery, [6] [7] [8] although 3 separate randomized clinical trials have been terminated early secondary to poor accrual. [9] [10] [11] Retrospective single and multi-institutional studies have shown both comparable and improved results with SBRT compared with surgery. [12] [13] [14] [15] [16] However, 2 recent large cohort studies reported decreased survival with SBRT compared with surgical resection, although these studies were not focused on wedge resection and considered larger T2 tumors. 17, 18 Limiting the comparison of SBRT and surgical resection to only surgical wedge resection may be more appropriate than considering all types of surgical resections, considering that both wedge resection and SBRT without additional lymph node sampling essentially limit treatment to only the immediate lung parenchyma in the area of a lung cancer. We hypothesized that surgical resection with wedge resection is associated with better survival than treatment with SBRT. Our study aim was to compare overall survival after management with SBRT and wedge resection in propensity score-matched patients. Unfortunately, a clinical trial that addresses this extremely important management question is unlikely to be completely in the near future, especially considering the multiple failures to complete trials that compare SBRT and surgery as described previously. Therefore, this study was undertaken to test our hypothesis by using the National Cancer Date Base (NCDB) to assemble a large cohort of patients with clinical-stage IA NSCLC who were treated with either wedge resection or SBRT.
MATERIAL AND METHODS National Cancer Data Base
The Duke University Institutional Review Board approved this retrospective review of the NCDB. The NCDB, established in 1989, is a nationwide, facility-based, comprehensive clinical surveillance resource oncology data set that currently captures 70% of all newly diagnosed malignancies in the United States annually. The NCDB is administered jointly by the American College of Surgeons and the American Cancer Society and collects data from more than 1500 cancer institutions. The database currently contains data from more than 30 million patient records. The American College of Surgeons has executed a Business Associate Agreement that includes a data use agreement with each of its Commission on Cancer-accredited hospitals. 19 All patients within the NCDB have histologic confirmation of their cancer diagnosis.
Study Population
Patients with clinical-stage IA NSCLC were identified by the use of International Classification of Disease for Oncology, 3rd Edition histology and topography codes. The tumor histology codes C34.0-C34.3 and C34.8-C34.9 were used, and those patients who underwent wedge resection or SBRT between 2008 and 2011 were selected for analysis. Patients who received radiation treatment before wedge resection or SBRT were excluded, but preoperative chemotherapy was not an exclusion criteria. We limited our analysis to patients with tumors less than or equal to 2 cm in accordance with current National Comprehensive Cancer Network guideline recommendations for use of sublobar resection for NSCLC. 20 
Statistical Analysis
Patients were grouped by whether they underwent SBRT or wedge resection. Wedge resection was the control, whereas SBRT was the exposure. Long-term survival (defined as the date of diagnosis to date of death from any cause and censored at date of most recent alive follow-up that is recorded in the NCDB) was the primary endpoint and was estimated with the Kaplan-Meier method 21 and compared between treatment modalities by use of the log-rank test and c 2 test. To reduce potential bias from patient selection, treatment group matching was performed with propensity scores. Logistic regression 22 was used to estimate the corresponding scores from the following covariates: age, sex, race, insurance status, Charlson-Deyo comorbidity score, facility type, histology type, tumor location, tumor size, and distance to hospital. Patients were matched by propensity scores via a 1:1 greedy algorithm. The matching macro used was OneToMany-MATCH. 23 In addition, we performed 2 separate propensity-matched subgroup analyses. To test the hypothesis of whether SBRT compromised survival in elderly patients, a subgroup analysis was performed with patients older than 80 years of age. To test the hypothesis of whether SBRT compromised survival in patients with multiple comorbidities, we performed a subgroup analysis in patients with a Charlson-Deyo comorbidity score of 2 or greater.
To further evaluate whether the results of the main analysis were biased by patients either being treated at centers inexperienced with 24 in which we analyzed the association of center performance (defined as a ratio of observed to expected [O/E] mortality) and the use of SBRT. A multivariate logistic regression model was created to predict mortality incorporating age, sex, race, insurance status, Charlson-Deyo comorbidity score, facility type, histology type, tumor location, tumor size, and distance to hospital. The risk model was then used to calculate the expected mortality for each center.
The observed mortality for each center was divided by the expected mortality to calculate the O/E ratio. Centers with an O/E > 1 had an increased mortality compared with what was expected given the characteristics of the patients they treated, meaning they performed worse than expected. Conversely, centers with an O/E < 1 had decreased mortality compared with expected, meaning they performed better than expected.
All centers were divided into quartiles based of their percentage use of SBRT as opposed to wedge resection. Centers with all SBRT patients, with all wedge resection patients, or with less than 5 patients were excluded from the analysis to make the analysis generalizable to established centers that perform both SBRT and surgical resection. This was also performed to decrease the bias associated with center-level analyses by decreasing the amount of variability between the centers being compared. The O/E ratios of the centers based off their percent use of SBRT were then compared with each other with the Cochran-Armitage test for trend. Quartiles were compared with the c 2 test. Complete case analysis was used for all adjusted analyses. All analyses were performed using SAS 9.4 (SAS Institute, Cary, NC).
RESULTS
A total of 6295 patients met study criteria, of whom 1778 (28.2%) received SBRT and 4517 (71.8%) received wedge resection ( Figure E1 ). Of the patients who received wedge resection, 528 (11.7%) were upstaged after operation from clinical IA to pathologic IB or greater. The median number of lymph nodes evaluated in the wedge resection group was 3 lymph nodes, and 2051 patients had no lymph nodes examined. In the overall study cohort, 2.8% and 5.3% received preprocedural chemotherapy for the SBRT and wedge resection group, respectively.
Patients who received SBRT were more likely to be older and have nonprivate insurance but less likely to Figure) . After propensity score matching, the 2 groups became similar with regard to their demographics and tumor characteristics ( Figure 1 ). After matching 1584 patients from each group, the 5-year survival in the SBRT group remained decreased at 31.0% (CI, 26.1%-36.0%) compared with a survival of 49.9% (CI, 45.1%-54.6%) in the wedge resection group (P <.001) (Figure 2 ).
Patients Older Than 80 Years Subgroup Analysis
To test whether SBRT compromised survival in the elderly, a subgroup analysis was performed in patients older than 80 years (Table 2 ). In the subgroup of 898 patients, 409 received SBRT and 489 patients underwent wedge resection. The wedge resection group had an improved 5-year survival of 40.1% (CI, 31.3%-48.8%) compared with 22.6% (CI, 13.8%-32.9%) for the SBRT group (P < .001). We similarly performed a propensity scorematched analysis with 319 patients from each group. In this cohort, a 5-year survival advantage still remained for the wedge resection group compared with the SBRT group respectively, (P ¼ .007) ( Figure E2 ).
Patients With a Charlson-Deyo Score of 2 or Greater Subgroup Analysis
To determine the effect of SBRT in a cohort with multiple comorbidities, another subgroup analysis was performed in patients with a Charlson-Deyo comorbidity score of 2 or greater (Table 3) . In this subgroup, 290 patients received SBRT and 805 patients underwent wedge resection. In this cohort, a 5-year survival advantage was seen in the wedge resection group (P < .001), which remained after we adjusted for patient and tumor characteristics (P ¼ .020) ( Figure E3 ).
Center-Level Analysis
Centers treating study patients were then compared by O/E ratios for survival. Centers were stratified then divided into 4 quartiles based off the percentage of SBRT patients relative to their overall cohort of study patients. The centers that predominantly performed wedge resections for their study patients were in the first quartile, whereas centers that mainly performed SBRT for their patients were in the fourth quartile. The quartiles did not differ in their makeup of academic and nonacademic facilities (all P > .05). O/E mortality was compared at 1 month, 1 year, 2 years, and 3 years from disease diagnosis with the use of multivariable logistic regression models for each time point separately. These centers were then stratified based on their use of SBRT versus wedge resection. A total of 223 centers initially met inclusion criteria.
At the 1-month time point ( Figure E4 ), a significant trend was observed (P ¼ .048) in which lower-quartile centers (predominantly wedge resection quartile) were less likely to have an O/E ratio less than 1 (performed better than expected) for 30-day mortality (Table 4) ; however, this trend was not present at the 1-year time point ( Figure E5 ). At the 2-year time point ( Figure E6 ), however, a significant trend was observed (P ¼ .005) in which lower-quartile centers more often had an O/E ratio less than 1. Conversely, the highest quartile (predominately SBRT quartile) more often had an O/E ratio greater than 1 (performed worse than expected). The trend continued into the 3-year time point and remained statistically significant (P ¼ .034) ( Figure 3) .
DISCUSSION
This comparative analysis of wedge resection with SBRT in patients thought to be surgical candidates is significant and informative. Among patients with clinical-stage IA NSCLC, we found that SBRT was associated with a significant survival disadvantage compared with wedge resection. This survival disadvantage was notable in both the overall cohort as well as in the subgroups of older patients and patients with comorbid disease. Finally, when analyzing the association between center use of SBRT and mortality, we found that SBRT use was associated with a higher center mortality than expected.
Although numerous phase 2 studies have demonstrated the efficacy of SBRT over external beam radiation in NSCLC patients deemed inoperable, [25] [26] [27] [28] [29] its role in the management of operable patients is still being defined. The landmark study by Zimmermann and colleagues 28 introduced SBRT into the field of thoracic oncology by demonstrating its efficacy over external beam radiation. Afterwards, the role of SBRT in replacement of surgery has been investigated actively. Initially, 2 phase 2 clinical trials opened in Japan and the United States investigating SBRT in operable patients with clinical-stage I NSCLC: the Japan Clinical Oncology Group (JCOG) 0403 and Radiation Therapy Oncology Group (RTOG) 0618, respectively. Recently published, JCOG 0403 reported a 3-year overall survival of 76.5%, 30 which is inconsistent with our observed unadjusted 3-year survival in our SBRT group.
A couple factors may account for the difference. The JCOG 0403 study required rigid criteria defining which patients were operable. Patients had to have an expected postoperative forced expiratory volume in 1 second>800 mL, a PaO 2 > 65 torr, no severe cardiac morbidity, and no severe diabetes mellitus. Defining operability outside of a clinical trial setting is difficult because this definition may be different between surgeons. In addition, patients in the study who fulfilled the operable criteria could afterwards be determined as inoperable by the study committee, which accounted for approximately one third of patients who met initial operable criteria being then being excluded after committee screening. Another possible factor that could explain the difference in survival is the fact that our SBRT group may be a sicker cohort of patients. The results of RTOG 0618 remain unpublished.
Previous retrospective analyses also have attempted to delineate the feasibility of SBRT in operable patients mainly through propensity score matching. 13, [15] [16] [17] 31 Shirvani and colleagues 15 reported outcomes from the Surveillance, Epidemiology, and End Results database of 9093 patients undergoing either lobectomy, sublobar resection, or SBRT, showing an improved survival with lobectomy when compared with sublobar resection and SBRT. However a limitation of this analysis and the Surveillance, Epidemiology, and End Results database is that it only captures ''best staging available,'' meaning if the initial therapy was surgery, the staging would be pathologic staging, and if the initial staging was radiation, the staging would be clinical staging. Without the delineation between clinical and pathologic staging, this limits the generalizability of the results. 14 ; they reported a 5-year overall survival of 69.5%. Again, stricter criteria defining operable patients providing a healthier subset of operable SBRT patients could possibly explain the difference between the results of these 2 studies versus ours. In addition, this difference may possibly be attributable to the efficacy of SBRT in the clinical research setting and the effectiveness of SBRT in practicality.
This study contributes significant information to the current literature regarding surgery versus SBRT. In another analysis, Puri and colleagues, 17 also using the NCDB, reported outcomes of 117,618 patients undergoing either surgical resection or SBRT. They showed a survival advantage for surgical resection. They also performed a subgroup analysis of patients who underwent sublobar resection compared with SBRT that also showed a survival advantage for resection.
Several analyses in our study merit consideration. We limited our analysis to small tumors (2 cm) 1 to allow for a comparison in a more homogenous population considered to be the ''best'' candidates for SBRT and thus minimizing bias. Also, by focusing specifically on wedge resection, we allow for the comparison of one surgical procedure with its known limitations to SBRT, again decreasing bias. In doing so, we found a higher potentially more accurate median survival in our SBRT group of 40.8 months compared with 33.1 months reported by Puri and colleagues. 17 Finally, our center-level sensitivity analysis strengthens our overall analysis and attempts to increase external validity by showing consistency between the results of our primary and sensitivity analysis. Our centerlevel analysis also shows a dose-response relationship between the use of SBRT and center mortality. All these factors enhance our ability to make a causal inference between SBRT and increased mortality in patients with early-stage NSCLC.
These issues related to observational research highlight the need for a prospective randomized clinical trial, but unfortunately this has not been achievable. First-quartile centers predominately used wedge resection, whereas fourth-quartile centers predominately used SBRT. Centers with either all SBRT patients, all wedge resection patients, or with less than 5 patients were excluded. Quartiles were compared using a ratio of observed mortality to expected mortality with an O/E 1 indicating similar or better performance than expected and an O/E > 1 indicating worse performance than expected. Depicted is center 3-year mortality O/E ratios. O/E, Observed to expected; %SBRT, percent stereotactic body radiotherapy use.
and it is likely to be several years before results are reported.
Despite the strong statistical methodology employed in our overall analysis, the overall survival advantage seen with wedge resection when compared with SBRT could possibly be secondary to selection bias. Recognizing the challenge, we used both propensity score matching on a patient level and O/E ratios for a center-level comparison to come to the same conclusion. Although this does not completely negate the selection bias, it strengthens the potential validity of our results.
In addition, not all wedge resection is limited to treatment of the immediate lung parenchyma, as many surgeons will perform concomitant lymphadenectomy. The additional value of lymph node sampling will, at a minimum, facilitate more accurate staging and determine adjuvant therapy. In our SBRT group, pathologically node-positive but clinically undetected cases were included as early-stage cancers and likely experienced worse survival, whereas the patients upstaged at surgery may have been offered additional therapy.
Our study has other limitations as well. First, as a limitation of our dataset, disease-free survival, diseasespecific survival, and locoregional recurrence could not be captured. Second, the quality of SBRT has evolved and improved over the years of the study, possibly making the SBRT overall survival less comparable with present-day SBRT. Furthermore, not all patients who underwent SBRT may have had tumors that were amenable to wedge resection. In fact, many may have had central tumors that required lobectomy or even pneumonectomy, so wedge resection was not even an option (and that is why they did not get a wedge resection). Third, the NCDB does not capture pulmonary function testing, which introduces another element for potential bias. Finally, our analysis was retrospective in nature and thus subjected to incompleteness of data and coding errors. Nonetheless, our study is the largest cohort study (27) to specifically compare wedge resection with SBRT in clinical-stage IA NSCLC (Video 1).
CONCLUSIONS
In conclusion, this analysis using the NCDB demonstrates that SBRT is associated with decreased survival compared with wedge resection for patients with clinicalstage IA NSCLC. Our results highlight the need for multidisciplinary involvement in the evaluation of patients with early-stage lung cancer and that operable patients should be counseled regarding the potential compromise in survival associated with SBRT even for tumors 2 cm in First-quartile centers predominately used wedge resection, whereas fourth-quartile centers predominately used SBRT. Centers with either all SBRT patients, all wedge resection patients, or with less than 5 patients were excluded. Quartiles were compared with a ratio of observed mortality to expected mortality with an O/E<1 indicating better performance than expected and an O/E>1 indicating worse performance than expected. Mortality was calculated at 1 month, 1 year, 2 years, and 3 years. O/E, Observed to expected.
size. Finally, prospective randomized studies to delineate the method of management for patients with early-stage NSCLC are needed. Until these trials are able to be completed, SBRT should be used very cautiously for patients who could potentially tolerate surgery so that survival of these patients is optimized.
Webcast
You can watch a Webcast of this AATS meeting presentation by going to: http://webcast.aats.org/2016/Video/ Monday/05-16-16_Hall_E_0810_Yerokun-800.mp4.
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Discussion
Dr W. Weder (Zurich, Switzerland). Dear Chairmen, colleagues, ladies, and gentlemen. I want to thank the Society for inviting me to discuss this very important contribution from Dr Yerokun and colleagues from Duke University. The comparison of SBRT and wedge resection for stage IA lung cancer is of great interest, and this paper will largely contribute to the current debate. The study, based on the National Cancer Data Base from 2003 to 2011, demonstrates that wedge resection was associated with a better survival for patients with stage IA lung cancer compared with those treated by SBRT. The only cohort for which SBRT was not associated with a worse survival were patients older than 80 years and a Charlson-Deyo comorbidity score of more than 2. In contrast to many studies in the literature, which use 3-year survival only, you report on 5-year and longer survival, which is important for assessing survival in early-stage lung cancer.
My questions. From an oncological standpoint, a 5-year survival of 32% for patients with stage IA treated by SBRT is unexpectedly poor and the difference to the 52% after wedge resection is unexpectedly large. What do you think has contributed to this result? Dr Yerokun. In terms of the difference in the survival advantage associated with wedge resection compared with SBRT, there are a couple of reasons that the difference could be so dramatic. Number one, this study describes a real-world practice setting as opposed to clinical trials, which are the main source of literature for SBRT. Number two, our patients could be sicker in different ways not captured by the NCDB. The NCDB does not capture pulmonary function tests; it doesn't capture comorbidities on a granular level. However, the dataset does use the Charlson-Deyo score, which is a well-validated comorbidity score. And, third, it could be selection bias. Selection bias is inherent to any retrospective cohort analysis. However, despite that, our propensity score-matched analysis and our center-level sensitively analysis attempted to decrease the selection bias. Although not perfect, we believe this to be a rigorous attempt to account for this.
The main argument in any retrospective cohort analysis comparing any surgical intervention with a nonsurgical intervention is that the patients are different, inherently in some way not captured. By analyzing this on a center level, we not only adjusted on the patient level with logistic regression modeling, we also were able to remove centers that solely focused on one approach, hoping that this would make our groups more homogeneous. This in essence reduces the selection bias even more so than just normal propensity score matching.
As we all know, randomized controlled trial data are the best source of literature to determine causation, but in the absence of a randomized control trial, we have to rely on retrospective data. Dr Weder. Thank you. How were the surgical procedures done, by video-assisted thoracoscopic surgery (VATS) or thoracotomy, and what was the 30-day mortality?
Dr Yerokun. In terms of VATS versus open, 40% were VATS, either thoracoscopic or robotic, and 60% were open, and the 30-day mortality in the SBRT group was 0 and in the wedge group was less than 1%.
Dr Weder. Which radiotherapy dose was used for SBRT, and was tissue diagnosis available for all patients treated by radiotherapy?
Dr Yerokun. The mean radiation dose for the SBRT group was 52 Gy, which is consistent with the latest phase 2 trial that was published, JCOG0403; their standard dose was 48 Gy. In terms of a diagnosis, the NCDB requires all things documented to be histologically confirmed.
Dr Weder. Preoperative chemotherapy was not an exclusion criterion, despite it not being indicated in stage IA lung cancer. So how many patients received preoperative chemotherapy and for what reasons and were all those patients treated by chemo equally distributed in both groups?
Dr Yerokun. As far as preoperative chemotherapy, there were 3.2% of patients in the SBRT group that received preoperative chemotherapy versus 6% in the wedge resection group, so not equally distributed. However, we did not think that this difference contributed to the dramatic survival advantage associated with wedge resection.
Dr Weder. And my last question. Surgically treated patients were upstaged in 10.7%. What were the consequences, adjuvant radiotherapy, adjuvant chemotherapy, conversion to lobectomy? Dr Yerokun. We didn't look at all those endpoints, but we were able to see that in the patients who were upstaged, that 10% of patients that were upstaged, the 5-year mortality was about 40% in that cohort.
Dr Weder. I want to congratulate you again on this very important contribution.
Dr R. Cerfolio (Birmingham, Ala).
First of all, I love your message, congratulations, but I was very surprised you didn't look at pulmonary function tests. How could you not match the patients on the single best predictor of longevity from emphysema-the percent diffusing capacity of the lungs for carbon monoxide and percent forced expiratory volume in 1 second? Isn't that more than just a flaw in the database? Did I miss it in your abstract? Didn't you match them on pulmonary function tests?
Dr Yerokun. No, the NCDB does not capture pulmonary function tests.
Dr Cerfolio. That's a major problem. I am shocked it wasn't in the limitation slide. I mean, people are going to die from their pulmonary disease if they have a terrible percent forced expiratory volume in 1 second and percent diffusing capacity of the lungs for carbon monoxide, and you use survival as an endpoint. Obviously, most get SBRT for this reason and it is almost always pulmonary function tests. So you have got to mention that, number one.
Number two, the second problem I have is you used wedge resection as a surrogate of being an experienced surgeon. I would argue guys who are doing wedges are surrogates of guys who aren't particular good or experienced surgeons.
Any comments on that? Dr Yerokun. The main reason for selecting wedge resection was because of its poor oncologic outcome, and we wanted to see whether the worst we had to offer as far as surgeons was better than SBRT.
Dr Cerfolio. No, I understand that, but you are using that as a surrogate of experienced surgeons. I would argue if you are doing more wedges, that is a surrogate of a lessexperienced surgeon. You should have looked at segmentectomy and lobectomy as surrogate of an experienced surgeon.
Thank you. Dr Yerokun. Thank you. Dr M. DeCamp (Chicago, Ill). Congratulations, a great paper, and one that will help us tremendously as we debate our radiation oncology colleagues. One of the small points you made was the number of lymph nodes sampled in the wedge resection group, and of course our SBRT colleagues don't have any nodal staging. What percentage of the surgical patients actually had any nodes sampled? We know that a number of those wedge resections were done with no nodal staging. This gets at your point about whether the patients in both groups are truly different. One of the most common arguments I have with my radiation colleagues is that SBRT is based on clinical staging, computed tomography, and positron emission tomography and really underestimates the true pathologic stage that they are proposing to treat.
Dr Yerokun. Thank you for your comment. We didn't look specifically at how many patients had lymph nodes extracted or had any lymph nodes. That is a good point, though, and something we can look for in the future. But I think your comment is definitely true and that is the reason we wanted to investigate this.
Dr Decamp. You reported a range of one to four nodes sampled, but there is likely a sizable population that had zero, and I think our SBRT colleagues will tease that out and focus on it.
Dr S. Cassivi (Rochester, Minn). Notwithstanding the comments that my other colleagues have made, I think your talk is an excellent one and one that will be listened to and your paper will be read by many people. So it is important. And ironically Cerf did not make the sports analogy, but I will. No one tunes into the sports channel to hear the scores at the end of the first period or at the end of the half; they want to know the score at the end of the game. What you have produced is a paper that shows us the end of the game. Rather than the papers or the studies that are in process that provide us with outcomes at one or three years, you provide us with outcomes at five and beyond, which I think are the most pertinent. So you are to be commended on that.
My question to you is, with your innovative piece at the end about looking at the different centers and the percentage of SBRT that they do, why did you cut it off at 3 years? Why not at 5? Was it an issue of trying to power your study enough? Why did you cut it off at 3? Dr Yerokun. Good question and thank you for your comment. The reason we cut it off at 3 years was a statistical issue in terms of censoring. The median follow-up was slightly more than 3 years in both groups. So if we go further than that, then more than 50% of the patients would have been censored and then it would have been a powering issue. Three years was where we had the right amount of power to detect a difference without worrying about censoring.
Dr T. Egan (Chapel Hill, NC). That was a nice presentation, but I'm afraid your data are pretty severely flawed, and this has nothing to do with the sports rivalry between UNC and Duke. But you have compared apples that got wedge resections to oranges that got stereotactic radiation therapy. We have been doing SBRT at UNC for a very long time, and our bias is to get patients to have surgical resections, and we offer SBRT to patients who are too sick to have wedge resections. So it is not at all a surprise that your long-term survival is worse with SBRT, and you absolutely need to look at disease-free survival. You already admitted that the patients with SBRT were older and they were likely sicker with more comorbidities and poorer pulmonary function tests.
So I don't think your results are at all surprising, and unfortunately it is only going to be with prospective, randomized, well-controlled studies that we will be able to answer this question.
Dr Yerokun. Thank you for your comment. I agree with you that really the best way to determine which one is better are randomized controlled trials.
As far as our analysis, we did limit the SBRT group to those that were deemed operable by their clinician. Although this is limited, it did remove a lot of those palliative patients. We also did a subgroup analysis of patients younger than 60 years with a Charlson-Deyo comorbidity score of 0, and in that subgroup analysis there were 641 patients in the wedge resection group and 67 patients in our SBRT group. A survival advantage was still seen with the wedge resection group compared with the SBRT group. We propensity matched that group as well, and there were 57 patients in each group and we still saw a survival advantage with wedge resection.
Unfortunately, with the NCDB we do not have diseasefree survival, and the Charlson-Deyo comorbidity score was actually better in the SBRT group as opposed to the wedge resection group in the overall analysis.
Dr P. Van Schil (Antwerp, Belgium). Thank you for this major contribution. I have one question. When we discuss with radiation oncologists, a hot item remains those patients who have local recurrent disease and come to salvage surgery for us. Do you have any idea how many of these patients who had SBRT had salvage surgery afterwards and what the results were?
Dr Yerokun. No, we didn't look at what happened to the SBRT group afterwards, but it is something we did talk about and something that would be interesting to follow up on. But thank you for your comment.
Dr Moon. Walter, one final question? Dr Weder. I just want to echo, it will be an important contribution, and all the data we have so far comparing SBRT with surgery are of a retrospective nature with its limitation. However, I believe if you could refine your manuscript by integrating answers to these various questions, I think it will be a very important contribution.
Congratulations again. Dr Yerokun. Thank you. Scatterplot is shown of centers stratified by their center ratio of SBRT/ wedge. First-quartile centers predominately used wedge resection, whereas fourth-quartile centers predominately used SBRT. Centers with either all SBRT patients, all wedge resection patients, or with less than 5 patients were excluded. Quartiles were compared with a ratio of observed mortality to expected mortality, with an O/E 1 indicating similar or better performance than expected and an O/E > 1 indicating worse performance than expected. Depicted is center 1-month mortality O/E ratios. O/E, Observed to expected; %SBRT, percent stereotactic body radiotherapy use. Scatter plot is shown of centers stratified by their center ratio of SBRT/ wedge. First-quartile centers predominately used wedge resection, whereas fourth-quartile centers predominately used SBRT. Centers with either all SBRT patients, all wedge resection patients, or with less than 5 patients were excluded. Quartiles were compared with a ratio of observed mortality to expected mortality with an O/E 1 indicating similar or better performance than expected and an O/E > 1 indicating worse performance than expected. Depicted is center 1-year mortality O/E ratios. O/E, Observed to expected; %SBRT, percent stereotactic body radiotherapy use.
FIGURE E6.
Center-level comparison of SBRT with wedge resection. Scatter plot is shown of centers stratified by their center ratio of SBRT/ wedge. First-quartile centers predominately used wedge resection, whereas fourth-quartile centers predominately used SBRT. Centers with either all SBRT patients, all wedge resection patients, or with less than 5 patients were excluded. Quartiles were compared with a ratio of observed mortality to expected mortality with an O/E 1 indicating similar or better performance than expected and an O/E > 1 indicating worse performance than expected. Depicted is center 2-year mortality O/E ratios. O/E, Observed to expected; %SBRT, percent stereotactic body radiotherapy use.
